Alimentary Pharmacology & Therapeutics

Systematic review: applications and future of gastric electrical stimulation
pp. 991-1002(12)
Authors: ZHANG, J.; CHEN, J. D. Z.

Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection
pp. 1003-1016(14)
Authors: KOHRT, H. E.; OUYANG, D. L.; KEEFFE, E. B.

The effects of tegaserod on oesophageal function and bolus transport in healthy volunteers: studies using concurrent high-resolution manometry and videofluoroscopy
pp. 1017-1027(11)
Authors: FOX, M.; MENNE, D.; STUTZ, B.; FRIED, M.; SCHWIZER, W.

The effect of sildenafil on segmental oesophageal motility and gastro-oesophageal reflux
pp. 1029-1036(8)
Authors: KIM, H. S.; CONKLIN, J. L.; PARK, H.

Effect of a proton pump inhibitor on postprandial gastric volume, emptying and symptoms in healthy human subjects: a pilot study
pp. 1037-1043(7)
Authors: GRUDELL, A. B. M.; CAMILLERI, M.; BURTON, D. D.; STEPHENS, D. A.

Influence of delaying gastric emptying on meal-related symptoms in healthy subjects
pp. 1045-1050(6)
Authors: TACK, J.; COULIE, B.; VERBEKE, K.; JANSSENS, J.

Type I autoimmune hepatitis: clinical course and outcome in an Italian multicentre study
pp. 1051-1057(7)
Authors: FLOREANI, A.; NIRO, G.; ROSA RIZZOTTO, E.; ANTONIAZZI, S.; FERRARA, F.; CARDERI, I.; BALDO, V.; PREMOLI, A.; OLIVERO, F.; MORELLO, E.; DURAZZO, M.

Endoscopic sphincterotomy with or without cholecystectomy for choledocholithiasis in high-risk surgical patients: a decision analysis
pp. 1059-1066(8)
Authors: SIDDIQUI, A. A.; MITROO, P.; KOWALSKI, T.; LOREN, D.

Cost-effectiveness of growth factors during hepatitis C anti-viral therapy
pp. 1067-1077(11)
Authors: CHAPKO, M. K.; DOMINITZ, J. A.

A randomized trial of pegylated-interferon-α2a plus ribavirin with or without amantadine in the re-treatment of patients with chronic hepatitis C not responding to standard interferon and ribavirin
pp. 1079-1086(8)
Authors: CIANCIO, A.; PICCIOTTO, A.; GIORDANINO, C.; SMEDILE, A.; TABONE, M.; MANCA, A.; MARENCO, G.; GARBAGNOLI, P.; ANDREONI, M.; CARITI, G.; CALLERI, G.; SARTORI, M.; CUSUMANO, S.; GRASSO, A.; RIZZI, R.; GALLO, M.; BASSO, M.; ANSELMO, M.; PERCARIO, G.; CICCONE, G.; RIZZETTO, M.; SARACCO, G.

Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study
pp. 1087-1097(11)
Authors: D'HAENS, G.; HOMMES, D.; ENGELS, L.; BAERT, F.; VAN DER WAAIJ, L.; CONNOR, P.; RAMAGE, J.; DEWIT, O.; PALMEN, M.; STEPHENSON, D.; JOSEPH, R.

Adherence rates with infliximab therapy in Crohn's disease
pp. 1099-1103(5)
Authors: KANE, S.; DIXON, L.

The +1059G/C polymorphism in the C-reactive protein (CRP) gene is associated with involvement of the terminal ileum and decreased serum CRP levels in patients with Crohn's disease
pp. 1105-1115(11)
Authors: THALMAIER, D.; DAMBACHER, J.; SEIDERER, J.; KONRAD, A.; SCHACHINGER, V.; PFENNIG, S.; OTTE, J.-M.; CRISPIN, A.; GÖKE, B.; OCHSENKÜHN, T.; LOHSE, P.; BRAND, S.

Participation in a clinical trial influences the future management of patients with gastro-oesophageal reflux disease in general practice
pp. 1117-1125(9)
Authors: MEINECHE-SCHMIDT, V.; HVENEGAARD, A.; JUHL, H. H.

Adipokines and gastrointestinal disease
pp. 1127-1128(2)
Authors: Beales, I. L. P.; Ogunwobi, O.

Adipokines and gastrointestinal disease: authors' reply
pp. 1129-1131(3)
Authors: John, B. J.; Irukulla, S.; Abulafi, A. M.; Kumar, D.; Mendall, M. A.